Literature DB >> 3266152

Single and multiple dose pharmacokinetics of tenoxicam in the elderly.

O G Nilsen1, R A Walstad, M Eckert, P Heizmann, A Bückert, T Am, I Løge, J Unnvik, E Thue.   

Abstract

Fourteen elderly subjects (10 women, 4 men) with a mean age of 81 (SD 6.7) years and in need of anti-inflammatory drug treatment were given a single dose of 20 mg tenoxicam. After a drug-free interval of 5 weeks, multiple dose treatment with 20 mg tenoxicam once daily for 56 days was initiated. The single and multiple dose kinetics of tenoxicam were investigated after HPLC determination of tenoxicam in the plasma. The elimination half-life of tenoxicam ranged from 44 to 132 h (mean 71.9 h) with no significant difference between the single and multiple dosage regimens. Tenoxicam reached maximum plasma concentrations after 1.4 and 1.1 h, with values of 3.6 and 15.5 micrograms.ml-1, for the single and multiple dosage regimen respectively. The corresponding trough values (24-h values) were 1.8 and 11.7 micrograms.ml-1. A mean accumulation ratio of 5.1 was calculated. The mean increase in the area under the plasma concentration time curves at steady-state was 21% more than predicted from the initial single dose. This deviation from linearity was considered to be of minor clinical significance. The kinetics of tenoxicam in elderly were similar to that published for young healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3266152     DOI: 10.1007/bf00558254

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly.

Authors:  H A Bird; R J Francis; P Le Gallez; J Hill; J S Dixon; J G Allen; V Wright
Journal:  Eur J Rheumatol Inflamm       Date:  1985

2.  A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid.

Authors:  H A Bird; J G Allen; J S Dixon; V Wright
Journal:  Br J Rheumatol       Date:  1985-11

3.  Determination of tenoxicam in human plasma by high-performance liquid chromatography.

Authors:  P Heizmann; J Körner; K Zinapold
Journal:  J Chromatogr       Date:  1986-01-10

4.  Pharmacokinetics of tenoxicam in healthy human volunteers.

Authors:  R C Heintz; T W Guentert; J F Enrico; U C Dubach; R Brandt; F S Jeunet
Journal:  Eur J Rheumatol Inflamm       Date:  1984

5.  Pharmacokinetics of tenoxicam in patients with impaired renal function.

Authors:  F F Horber; T W Guentert; E Weidekamm; P Heizmann; C Descoeudres; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  5 in total
  4 in total

Review 1.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 2.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 3.  Tenoxicam and renal function.

Authors:  R C Heintz
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.